Patents by Inventor John BOTSON

John BOTSON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • REDUCING IMMUNOGENICITY TO PEGLOTICASE
    Publication number: 20230173035
    Abstract: The disclosure provides methods of treating gout in patients comprising administering a PEGylated uricase. Also provided are methods of treating gout in patients comprising co-administering a PEGylated uricase and methotrexate (MTX). Also provided are methods of reducing immunogenicity of a PEGylated uricase and prolonging the urate lowering effect comprising co-administration of the PEGylated uricase and MTX.
    Type: Application
    Filed: September 28, 2022
    Publication date: June 8, 2023
    Inventors: Jeffrey D. KENT, Brian LAMOREAUX, John BOTSON, Jeff PETERSON
  • REDUCING IMMUNOGENICITY TO PEGLOTICASE
    Publication number: 20220409620
    Abstract: The disclosure provides methods of treating gout in patients comprising administering a PEGylated uricase. Also provided are methods of treating gout in patients comprising co-administering a PEGylated uricase and methotrexate (MTX). Also provided are methods of reducing immunogenicity of a PEGylated uricase and prolonging the urate lowering effect comprising co-administration of the PEGylated uricase and MTX.
    Type: Application
    Filed: June 1, 2021
    Publication date: December 29, 2022
    Inventors: Jeffrey D. KENT, Brian LAMOREAUX, John BOTSON, Jeff PETERSON
  • REDUCING IMMUNOGENICITY TO PEGLOTICASE
    Publication number: 20200237881
    Abstract: The disclosure provides methods of treating gout in patients comprising administering a PEGylated uricase. Also provided are methods of treating gout in patients comprising co-administering a PEGylated uricase and methotrexate (MTX). Also provided are methods of reducing immunogenicity of a PEGylated uricase and prolonging the urate lowering effect comprising co-administration of the PEGylated uricase and MTX.
    Type: Application
    Filed: January 30, 2020
    Publication date: July 30, 2020
    Inventors: Jeffrey D. KENT, Brian LAMOREAUX, John BOTSON, Jeff PETERSON